EACS2023: 516 Who wants to switch to injectables? Patients’ preferences, perceptions and knowledge in the Swiss HIV Cohort Study Y. Martin , B. Surial , D. Jackson-Perry , D. Haerry , A. Hachfeld , C. Béguelin , M. Bürgi , A. Munting , M. Cavassini , D. Braun , A. Rauch , R. Auer , G. Wandeler Inselspital, Bern University Hospital, University of Bern, Department of Infectious Diseases, Bern, Switzerland, University Hospital and University of Lausanne, Service of Infectious Diseases, Lausanne, Switzerland, Positive Council, Bern, Switzerland, Spitalzentrum Biel, Department of Internal Medicine, Biel/Bienne, Switzerland, University Hospital Zurich, University of Zurich, Department of Infectious Diseases and Hospital Epidemiology, Zurich, Switzerland, Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland, Centre for Primary Care and Public Health (Unisanté), Lausanne, Switzerland General data Abstract category: Antiretroviral therapy – observational studies Abstract body Purpose: Initiating injectable long acting antiretroviral therapy (iLA-ART) or continuing oral ART (oART) is a preference-sensitive decision. While iLA-ART is widely available in Switzerland, we assessed the preferences and values of persons with HIV (PWH) regarding ART and their knowledge about iLA-ART. Method: Consecutive PWH on oART seen at three centers of the Swiss HIV Cohort Study (SHCS) were asked to fill out questionnaires assessing 1) general values and preferences about oART and iLA-ART, 2) burden of treatment on current ART, and 3) knowledge about iLA-ART. Expert patients co-developed questionnaires. Responses were presented using a 10-point Likert scale. We explored predictors of knowledge about iLA-ART using multivariable logistic regression. Results: Of 228 SHCS participants considered, 185 (81.1%) accepted to fill out the questionnaires. The most valued ART characteristics were effectiveness (mean 9.9/10, standard deviation [SD] 0.3) and absence of side-effects (mean 9.6/10, SD 1.5). Burden of treatment on oART was low (mean 2.4/10, SD 1.9) and treatment satisfaction was high (mean 9.3/10, SD 1.3). Overall, 68 (37%) participants had never heard about iLA-ART. In multivariable analyses, men were more likely to know about iLAART than women (64% vs 52%, p=0.02), whereas participants >60 years were less likely to have this knowledge (45% vs 77% among 18-39 years, p=0.02). Participants who reported a preference for staying on oART (33%) feared losing freedom if switching to iLA-ART (mean 7.7/10, SD 2.8), and would be interested in iLA-ART if dosing intervals were 6 months (mean 6.7/10, SD 3.8). Conclusions: Effectiveness and tolerability of modern oART help explain the high treatment satisfaction and low burden of treatment among PWH. Relatively short dosing intervals of iLA-ART seem to discourage many PWH to initiate a switch to iLAART. Knowledge gaps about iLA-ART should be addressed to help PWH choose the treatment strategy that best fits their preferences. General conditions 1. I confirm that I previewed this abstract and that all information is correct. I accept that the content of this abstract cannot be modified or corrected after the submission deadline and I am aware that it will be published exactly as submitted.: Yes 2. I confirm that the submission of the abstract constitutes my consent to publication (e.g. conference website, programmes, other promotions, etc.). : Yes 3. I herewith confirm that the contact details saved in this system are those of the corresponding author, who will be notified about the status of the abstract. The corresponding author is responsible for informing the other authors about the status of the abstract.: Yes 4. I agree that all data provided may be used (saved, stored, processed, transmitted and deleted) in compliance with the privacy policy to provide the services described.: Yes 1 1 2 3 1 4,1 4 2 2 5 1 6,7 1 1 2 3 4 5 6 7 129
RkJQdWJsaXNoZXIy Mzc2ODc=